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incidence of PVE, which is most often due to hospital acquired
pathogens
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Background: Staphylococcus aureus bacteremia (SAB) is one
of the serious nosocomial or community acquired infections. SAB
can persist longer as compared to bacteremia with other bacteria,
althoughwhether risk factors associatedwith persistent SABwhich
pointed out in previous studies are related to its persistency of SAB
in the settings with different antibiotic resistant rate and different
antibiotic use. In this study, we determined clinical characteristics
and risk factors for persistent SAB by comparing persistent SAB
cases and non-persistent SAB cases in Japan.
Methods & Materials: All the ﬁrst episodes of adult SAB cases
in 1,150 bed academic medical hospital in Japan form May 2009
through April 2014 were enrolled. The onset of SAB was deﬁned
as the time when the ﬁrst positive blood cultures were collected.
Persistent SABwas deﬁned as a case inwhich positive blood culture
persisted 72 hours or longer, and non-persistent SAB was deﬁned
as a case negativity of blood culture was veriﬁed within 72 hours.
Clinical backgrounds, primary infection sites, methicillin resistant
or not (MRSA or MSSA), vancomycin susceptibility, and antibiotic
use were retrospectively reviewed from medical records.
Results: Of 618 SAB cases, MRSA cases and MSSA cases were
293 and 325 cases, respectively. Persistent SAB were 42 cases,
non-persistent SAB were 34 cases. Median persistent periods of
persistent SAB and non-persistent SAB were 2 days and 8 days,
respectively. Clinical backgrounds and primary infection sites pri-
mary infection sites were similar between the two groups. The rate
of MRSA was in persistent SAB was statistically higher than that
of non-persistent SAB (93% vs 35%, P<0.001)(Fig. 1). Although sus-
ceptibilities to vancomycin, were similar between the two groups,
the timing of susceptible antibiotics use in persistent SAB was later
than that in non-persistent SAB (2 days vs 0 days, P <0.001) (Fig. 2).
Fig. 1. Methicillin susceptibility of SA and SAB persistence.
Fig. 2. Delay of antibiotic use and SAB persistence.
Conclusion: In our study, persistence of SAB were associated
with MRSA as a pathogen, delay in susceptible antibiotic use, but
notwith clinical backgroundsnorwithvancomycin susceptibilities.
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Background: The rising incidence and worsening severity of
Clostridium difﬁcile infection (CDI) have prompted improvements
in the treatment of CDI in many countries. Vancomycin (VCM) and
Metronidazole (MNZ) are both widely used. VCM may bring about
a better clinical response and outcome than MNZ in treating CDI,
especially severe CDI. The optimal treatment for CDI, however, has
yet tobeestablished in Japan.Dosages anddurationsofmedications
for CDI have not been clearly described in previous studies, and
MNZ has only recently been approved for CDI under the national
health insurance system. Our group conducted Japan’s ﬁrst multi-
center retrospective study to investigate the optimal treatment
for CDI by comparing outcomes between MNZ- and VCM-treated
groups at variable dosages and treatment durations.
Methods & Materials: CDI patients hospitalized at four teach-
ing hospitals from April 2012 through September 2013 were
enrolled. CDIwasdiagnosedwhenCD toxinwaspositivebyenzyme
immunoassay test in stool. Thepatientswere treated for 10-14days
with oral MNZ (1000 or 1500 mg per day: MNZ group) or oral VCM
(500 mg per day: VCM group). Kaplan-Meier curves were created
to compare the survival curves between MNZ- and VCM-treated
patients.
